Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cytokinetics (CYTK)
NASDAQ:CYTK
Holding CYTK?
Track your performance easily
CYTK Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$25.98 - $110.25
Previous Close$55.88
Volume879.89K
Average Volume (3M)1.40M
Market Cap
$6.57B
Enterprise Value$5.76B
Total Cash (Recent Filing)$1.06B
Total Debt (Recent Filing)$239.58M
Price to Earnings (P/E)―
Beta0.77
Next Earnings
Oct 31, 2024EPS Estimate
-$1.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.37
Shares Outstanding117,659,578
10 Day Avg. Volume1,177,196
30 Day Avg. Volume1,398,992
Standard Deviation0.24
R-Squared0.03
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)60.74
Price to Sales (P/S)2097.90
Price to Cash Flow (P/CF)-16.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.84K
Enterprise Value/Gross Profit-17.85
Enterprise Value/Ebitda-16.64
Forecast
1Y Price Target
$81.85Price Target Upside46.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
Cytokinetics News
Bulls Say, Bears Say
Bulls Say
Clinical AdvancementsCK-586 demonstrated ability to decrease the number of active myosin cross-bridges during cardiac contraction and reduce contractile force, without affecting calcium signaling.
Market PotentialManagement anticipates >80% of the market would be CMI-eligible, allowing for aficamten's differentiated benefit-risk profile to elevate market positioning as 'CMI of choice'.
Regulatory ProgressFDA allowing for less frequent echocardiographic monitoring in maintenance oHCM patients in FOREST-HCM, which bodes well for a distinct risk mitigation program for aficamten label.
Bears Say
Commercial BarriersKOLs warned the commercial barriers may be high, with most feeling that SGLT2s would likely receive a Class 1 recommendation in the next guidelines.
Financial PerformanceThe deals' related dilution and increased long-term operating expenses trajectory resulted in a lower price target.
Safety ConcernsSafety was more problematic, where beyond high rates of GI issues, one patient’s LVEF dropped below 50%, raising the prospect of a potential REMS with negative commercial read-throughs.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
CYTK FAQ
What was Cytokinetics’s price range in the past 12 months?
Cytokinetics lowest stock price was $25.98 and its highest was $110.25 in the past 12 months.
What is Cytokinetics’s market cap?
Currently, no data Available
When is Cytokinetics’s upcoming earnings report date?
Cytokinetics’s upcoming earnings report date is Oct 31, 2024 which is in 45 days.
How were Cytokinetics’s earnings last quarter?
Cytokinetics released its earnings results on Aug 08, 2024. The company reported -$1.31 earnings per share for the quarter, missing the consensus estimate of -$1.057 by -$0.253.
Is Cytokinetics overvalued?
According to Wall Street analysts Cytokinetics’s price is currently Undervalued.
Does Cytokinetics pay dividends?
Cytokinetics does not currently pay dividends.
What is Cytokinetics’s EPS estimate?
Cytokinetics’s EPS estimate is -$1.24.
How many shares outstanding does Cytokinetics have?
Cytokinetics has 117,659,580 shares outstanding.
What happened to Cytokinetics’s price movement after its last earnings report?
Cytokinetics reported an EPS of -$1.31 in its last earnings report, missing expectations of -$1.057. Following the earnings report the stock price went up 3.315%.
Which hedge fund is a major shareholder of Cytokinetics?
Among the largest hedge funds holding Cytokinetics’s share is Fisher Asset Management LLC. It holds Cytokinetics’s shares valued at 29M.
---
Cytokinetics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$81.85 (46.47% Upside)
$81.85 (46.47% Upside)
Blogger Sentiment
Bullish
CYTK Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 161.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $8.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.6%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
60.43%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
95.38%
Trailing 12-Months
Company Description
Cytokinetics
Cytokinetics, Inc. operates as a biopharmaceutical company, which focuses on the discovery and development of muscle activators as potential treatment for debilitating diseases. It conducts a Phase 2 clinical trials program for tirasemtiv, including a Phase 2b clinical trial in patients with ALS, known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). The company was founded on August 5, 1997 and is headquartered in South San Francisco, CA.
---
CYTK Earnings Call
Q2 2024
0:00 / 0:00
---
CYTK Stock 12 Month Forecast
Average Price Target
$81.85
▲(46.47% Upside)
Technical Analysis
Best Analysts Covering CYTK
1 Year
1 Year Success Rate
18/25 ratings generated profit
1 Year Average Return
+34.58%
reiterated a buy rating 9 months ago
Copying Charles Duncan's trades and holding each position for 1 Year would result in 72.00% of your transactions generating a profit, with an average return of +34.58% per trade.
---